{"schema_version":"1.0","type":"article","title":"AI製藥下半場：讓藥活下來","url":"https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.md","lang":"zh-Hant","date":"2026-06-13","publish_at":"2026-06-13T01:24:16.130Z","updated_at":"2026-06-13","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"AI 醫藥上半場比生成分子，下半場比成藥存活率。安宏真正值得被看見的，不是單純曝光，而是用 AI + PROTAC（蛋白質降解技術）、實驗閉環與人體轉譯，嘗試形成高資本效率的 clinical asset engine（臨床資產生成引擎）。","key_points":[],"facts":[],"sections":["輝達 NVIDIA 連續看見安宏背後，台灣 AI + PROTAC 成藥飛輪正在成形","01｜AI 醫藥正在換題目：不是生成更多分子，而是讓藥活下來","02｜連續三年進入 NVIDIA 生態圈：曝光背後，是生態位階的改變","03｜全球 AI 醫藥交易潮：大藥廠買的不是工具，而是成藥能力","04｜資本效率與臨床速度：安宏為何不只是 AI 新藥公司？","05｜安宏 AI + PROTAC 成藥飛輪引擎：AH-001 不是終點，而是 proof of engine","06｜全球 AI 原生代表性藥物：真正拉開差距的是誰能更快推進臨床","07｜安宏真正要證明的，是「活藥能力」","結語｜AI 製藥下半場，誰能讓藥活下來？"],"references":[{"title":"各公司官網＆公開資料","source":"","date":"","url":""},{"title":"NVIDIA × Lilly","source":"AI Factory / AI co-innovation lab","date":"","url":""},{"title":"NVIDIA","source":"","date":"","url":""},{"title":"NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.","source":"","date":"","url":""},{"title":"nvidianews.nvidia.com","source":"","date":"","url":""},{"title":"NVIDIA BioNeMo","source":"AI drug discovery foundation model / toolkit","date":"","url":""},{"title":"NVIDIA","source":"","date":"","url":""},{"title":"Access open-source tools, pretrained models, and GPU-accelerated pipelines to build AI solutions for drug discovery, medical imaging, genomics, healthcare robotics, and digital health.","source":"","date":"","url":""},{"title":"www.nvidia.com","source":"","date":"","url":""},{"title":"安宏生醫","source":"NVIDIA AI Summit / AI 蛋白質降解新藥研發成果","date":"","url":""},{"title":"安宏生醫在 NVIDIA AI Summit 發表 AI 蛋白質降解新藥研發成果 - AnHorn Medicines","source":"","date":"","url":""},{"title":"安宏生醫即將再度於6月5日參加在台北舉行的「NVIDIA AI Summit」分享其運用自主開發AI新藥開發平台，進行蛋白質降解新藥研發，成為此次唯一現場主講的台灣新藥研發公司。公司旗下第一個透過AI輔助設計的全新專利新藥，也將於今（2024）年申請新藥臨床試驗許可。","source":"","date":"","url":""},{"title":"www.anhornmed.com","source":"","date":"","url":""},{"title":"安宏生醫","source":"GTC 2026 開場影片再度曝光 / AH-001 國際潛力","date":"","url":""},{"title":"安宏生醫AI新藥研發成果登上輝達GTC舞台 AH-001展現國際潛力 - 生技投資第一站-Genet 觀點","source":"","date":"","url":""},{"title":"全球AI科技領袖黃仁勳於 GTC 2026 開場影片中，再次以動畫呈現人工智慧在新藥研發的應用。其中，安宏生醫以AI加速藥物設計與開發的成果受到聚焦，凸顯AI正逐步重塑全球新藥研發模式，推動從分子設計邁向臨床驗證的進程。 安宏生醫專注於 AI驅動的新藥研發，並聚焦於蛋白質降解創新藥物平台。首項進入臨床的產品 AH-001，鎖定治療雄性禿（雄激素性脫髮），以全新機制切入疾病根源，提供有別於現行療法的新一代解決方案。 雄性禿是一種影響男女的常見慢性落髮疾病，全球患者超過10億人。隨著外貌管理意識提升與美容醫療","source":"","date":"","url":""},{"title":"www.genetinfo.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：AI製藥下半場：讓藥活下來（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-01.webp"},{"alt":"Dcard 原圖：AI製藥下半場：讓藥活下來（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-02.png"},{"alt":"Dcard 原圖：AI製藥下半場：讓藥活下來（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-03.png"},{"alt":"Dcard 原圖：AI製藥下半場：讓藥活下來（圖 4）","url":"https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-04.png"},{"alt":"Dcard 原圖：AI製藥下半場：讓藥活下來（圖 5）","url":"https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-05.png"},{"alt":"Dcard 原圖：AI製藥下半場：讓藥活下來（圖 6）","url":"https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-06.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261654701/cover-ai-drug-survival.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-13）。AI製藥下半場：讓藥活下來。https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-13-anhorn-ai-drug-development-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}